Neos Therapeutics, Inc. (NEOS)
| Market Cap | 41.99M |
| Revenue (ttm) | 56.99M |
| Net Income (ttm) | -21.86M |
| Shares Out | 49.76M |
| EPS (ttm) | -0.44 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | March 4 |
| Last Price | $0.749 |
| Previous Close | $0.803 |
| Change ($) | -0.053 |
| Change (%) | -6.65% |
| Day's Open | 0.790 |
| Day's Range | 0.740 - 0.799 |
| Day's Volume | 829,859 |
| 52-Week Range | 0.450 - 1.500 |
– Record date for each Special Meeting of Stockholders is February 5, 2021 –
Penny stocks are wildly dangerous and not meant for risk-averse investors. Still, if you want to play, here are some ideas.
DALLAS and FORT WORTH, Texas, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq: NEOS), a commercial-stage pharmaceutical company developing and manufacturing central nervous s...
NEW YORK, Dec. 10, 2020 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by Neos Therapeutics, Inc. (NASDAQ: NEOS) and its board of directors concerning the...
NEW YORK, Dec. 10, 2020 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Neos Therapeutics, Inc. ("NEO...
Neos Therapeutics (NEOS) news for Thursday concerning a merger with Aytu BioScience (AYTU) has shares of NEOS and AYTU stock on the rise. The post Neos Therapeutics News: Why NEOS Stock Is Soa...
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Neos Therapeutics, Inc. (NASDAQ: NEOS) to Aytu BioScience, Inc. is fair to ...
Neos Therapeutics' (NEOS) CEO Jerry McLaughlin on Q3 2020 Results - Earnings Call Transcript
DALLAS and FORT WORTH, Texas, Nov. 02, 2020 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq: NEOS), a commercial-stage pharmaceutical company developing and manufacturing central nervous s...
Penny stocks have become a popular investment alternative in 2020's volatile corona-economy. Here's a look at 7 penny stock to watch in November.
DALLAS and FORT WORTH, Texas, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq: NEOS), a commercial-stage pharmaceutical company developing and manufacturing central nervou...
Neos Therapeutics, Inc. (NEOS) CEO Jerry McLaughlin on Q2 2020 Results - Earnings Call Transcript
– Company to host conference call today at 8:30 a.m. EDT – – Company to host conference call today at 8:30 a.m. EDT –
DALLAS and FORT WORTH, Texas, Aug. 03, 2020 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq: NEOS), a commercial-stage pharmaceutical company developing and manufacturing central nervous...
DALLAS and FORT WORTH, Texas, June 16, 2020 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq: NEOS), a commercial-stage pharmaceutical company developing and manufacturing central nervous...
Neos Therapeutics. Inc. (NEOS) CEO Jerry McLaughlin on Q1 2020 Results - Earnings Call Transcript
-- N-desethyloxybutynin is the active ingredient in NT0502, the company’s development candidate for the treatment of sialorrhea -- -- N-desethyloxybutynin is the active ingredient in NT0502, t...
Neos Therapeutics, Inc. (NEOS) CEO Jerry McLaughlin on Q4 2019 Results - Earnings Call Transcript
Neos Therapeutics Valuation Appears Low Should They Report Operating Profits In 2020
New chemical entity and selective muscarinic receptor antagonist targeting large unmet need for a new treatment that can meaningfully improve the lives of patients with neurological conditions...
Improvements At Neos Therapeutics Aren't Reflected In The Share Price
Neos Therapeutics, Inc. (NEOS) CEO Jerry McLaughlin on Q3 2019 Results - Earnings Call Transcript
DALLAS and FORT WORTH, Texas, Sept. 25, 2019 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq: NEOS), a commercial-stage pharmaceutical company utilizing its novel microparticle delivery ...
DALLAS and FORT WORTH, Texas, Aug. 29, 2019 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq: NEOS), a commercial-stage pharmaceutical company utilizing its novel microparticle delivery t...
Neos Therapeutics, Inc. (NEOS) CEO Jerry McLaughlin on Q2 2019 Results - Earnings Call Transcript
Neos Therapeutics (NEOS) delivered earnings and revenue surprises of 50.00% and -6.33%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Neos Therapeutics has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.
Neos Therapeutics, Inc. (NEOS) CEO Jerry McLaughlin on Q1 2019 Results - Earnings Call Transcript
Neos Therapeutics (NEOS) delivered earnings and revenue surprises of 31.82% and 3.06%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Neos Therapeutics (NEOS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Investors need to pay close attention to Neos Therapeutics (NEOS) stock based on the movements in the options market lately.
Neos Therapeutics, Inc. (NEOS) CEO Jerry McLaughlin on Q4 2018 Results - Earnings Call Transcript
About NEOS
Neos Therapeutics, a pharmaceutical company, develops, manufactures, and commercializes products for the treatment of attention deficit hyperactivity disorder (ADHD) using its drug delivery technology platform. Its products are extended-release (XR) medications in orally disintegrating tablets or liquid suspension dosage forms. The company manufactures and markets Adzenys XR-ODT amphetamine for the treatment of ADHD; Cotempla XR-ODT methylphenidate to treat ADHD; Adzenys ER amphetamine for the treatment of ADHD; and generic Tussionex, a hydroco... [Read more...]
| Industry Drug Manufacturers-Specialty & Generic | IPO Date Jul 23, 2015 |
| CEO Gerald McLaughlin | Employees 213 |
| Stock Exchange NASDAQ | Ticker Symbol NEOS |
Financial Performance
In 2019, NEOS's revenue was $64.65 million, an increase of 29.33% compared to the previous year's $49.99 million. Losses were -$16.90 million, -67.29% less than in 2018.
Analyst Forecasts
According to one analyst, the rating for NEOS stock is "Strong Buy" and the 12-month stock price forecast is 1.00.